Siemens Healthineers AG

SHL

Equity

ISIN DE000SHL1006 / Valor 40652181

Xetra (2024-09-17)

EUR 50.00+1.19%

Siemens Healthineers AG
UMushroom community rating:

4.60 5 votes No rating yet

NegativeNeutralPositive

About company

Siemens Healthineers AG is a leading global medical technology company that specializes in diagnostic and therapeutic solutions across a wide range of healthcare needs. With a strong focus on innovation, the company invests significantly in research and development, holding around 23,000 technical intellectual property rights, including over 14,000 granted patents as of October 2021. Siemens Healthineers aims to enhance patient care by providing cutting-edge technologies that support clinical decision-making and treatment pathways. The company's portfolio includes advancements in imaging, laboratory diagnostics, and minimally invasive therapies, among others. Operating in more than 70 countries, Siemens Healthineers is committed to making healthcare more accessible and effective worldwide, leveraging its extensive expertise to meet local market needs. The company's history of innovation dates back over 125 years, with a legacy that includes the development of the first medical X-ray device shortly after X-rays were discovered. Today, Siemens Healthineers continues to push the boundaries of medical technology, striving to improve outcomes for patients globally.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the third quarter of fiscal year 2024, Siemens Healthineers AG reported revenue of approximately €5.4 billion, reflecting a comparable revenue growth of 4.3%. This growth was achieved despite continued order delays in China, with significant contributions from the Americas and EMEA regions.

Adjusted EBIT

Siemens Healthineers AG's adjusted EBIT for Q3 FY 2024 increased by 9% year-on-year to €825 million. This resulted in an adjusted EBIT margin of 15.2%, which was higher than the prior-year quarter. The increase was driven by earnings improvements in the Diagnostics business and offsetting negative currency effects.

Net Income

Net income for Siemens Healthineers AG in the third quarter of fiscal year 2024 was €472 million, marking a 5% increase over the prior-year period. The tax rate for the quarter was 21%, higher than the 13% rate in the previous year, impacting the net income growth.

Free Cash Flow

Free cash flow for Siemens Healthineers AG reached €546 million in Q3 FY 2024, significantly higher than the prior-year quarter. This increase was primarily due to a reduction in receivables, which positively impacted the cash flow.

Outlook for Fiscal Year 2024

Siemens Healthineers AG has confirmed its outlook for fiscal year 2024, expecting comparable revenue growth between 4.5% and 6.5%, or between 5.0% and 7.0% excluding revenue from rapid COVID-19 antigen tests. The company also anticipates adjusted basic earnings per share to be between €2.10 and €2.30.

Summarized from source with an LLMView Source

Key figures

8.39%1Y

-14.7%3Y

38.8%5Y

Performance

20.1%1Y

26.7%3Y

27.2%5Y

Volatility